Holen Sie sich die Stockscreener-App
0.104
0.68%
0.0007
Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten
Aspire Biopharma Approves Key Proposals at Special Meeting - MSN
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - The Patriot Ledger
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - St. Cloud Times
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits
FDA feedback clears path for Aspire Biopharma’s heart attack drug By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug By Investing.com - Investing.com South Africa
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug - Investing.com Canada
FDA feedback clears path for Aspire Biopharma’s heart attack drug - Investing.com India
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - ACCESS Newswire
FDA backs trial of faster-acting aspirin powder for heart attacks - Stock Titan
Aspire Biopharma Provides Q3 2025 Business Update - Oak Ridger
Aspire Biopharma (ASBP) Competitors and Alternatives 2026 - MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aspire Biopharma Restructures Debt via Equity Exchange Agreements - TipRanks
Aspire Biopharma Holdings Signs Debt-for-Equity Exchange Agreements With Certain Debt Holders - TradingView — Track All Markets
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Asbury Park Press
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aspire Biopharma Holdings, Inc. Announces CEO Transition - aberdeennews.com
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Pensacola News Journal
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs Revenue Breakdown – NASDAQ:ASBPW - TradingView — Track All Markets
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs - TradingView — Track All Markets
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Bluffton Today
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine - The Florida Times-Union
ASBPAI Stock Analysis - Meyka
Aspire Biopharma welcomes Ashley Paulson as Brand Ambassador - Comunicaffe International
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Gl - The National Law Review
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aspire Biopharma names Ashley Paulson BUZZ BOMB global brand ambassador - TipRanks
Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching - ts2.tech
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):